XML 14 R35.htm IDEA: XBRL DOCUMENT v3.19.3

Collaboration and License Agreements (Details) $ in Thousands, € in Millions	1 Months Ended							3 Months Ended				6 Months Ended	9 Months Ended			12 Months Ended
	Feb. 28, 2019 USD ($)	Nov. 30, 2017 USD ($)	Oct. 31, 2017 USD ($)	Nov. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Oct. 31, 2014 USD ($)	Oct. 31, 2014 EUR (€)	Sep. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Collaboration and License Agreements [Abstract]
Sanofi termination cash payment								$ 208,000
Sanofi future cash payment								52,000
Sanofi Upfront Payment				$ 300,000
Sanofi Development Milestones				110,000
Sanofi Regulatory Milestones				220,000
Sanofi Outcomes Study Milestone				100,000
Sanofi Sales Milestone Payments				990,000
Sanofi Commercialization Costs Funded by Lexicon Maximum Amount				100,000
Sanofi Revenue Allocated to License Deliverable				126,800
Sanofi Revenue Allocated to Development Deliverable				113,800
Sanofi Revenue Allocated to Funding Deliverable				$ 59,400
Deferred revenue balance								23,500					$ 23,500
lxrx_Sanofi termination agreement								260,000
Sanofi Revenue Recognized													286,000	$ 25,600
Ipsen Total Payments								$ 47,200					47,200
Ipsen Maximum Regulatory And Commercial Milestones													9,600
Ipsen Maximum Sales Milestones | €							€ 72
Ipsen Total Upfront Payments					$ 24,500
Ipsen Milestone Payment											$ 6,400			5,100	$ 6,400
Ipsen Milestone Payment Received	$ 2,250	$ 3,840	$ 3,840						$ 1,250	$ 5,100
Ipsen Revenue Allocated to License Deliverable																$ 1,400	$ 21,200
Ipsen Revenue Allocated to Development Deliverable						$ 1,700
Ipsen Revenue Allocated to Committee Deliverable						$ 100
Ipsen Revenue Recognized													3,500	1,100
Ipsen Royalty Income_LXRX												$ 100	300	200
Ipsen Product Revenue													$ 1,300	$ 1,400

X

- Definition

Collaboration and License Agreements [Abstract]

+ References

No definition available.

+ Details

Name:	lxrx_CollaborationAndLicenseAgreementsAbstract
Namespace Prefix:	lxrx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenMaximumRegulatoryAndCommercialMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenMaximumSalesMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenMilestonePayment
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenMilestonePaymentReceived
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Ipsen Product Revenue - Product revenue sales to Ipsen for XERMELO

+ References

No definition available.

+ Details

Name:	lxrx_IpsenProductRevenue
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRevenueAllocatedtoLicenseDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRevenueRecognized
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenRoyaltyIncome_LXRX
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenTotalPayments
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.

+ References

No definition available.

+ Details

Name:	lxrx_IpsenTotalUpfrontPayments
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

lxrx_Sanofi termination agreement - represents the full cash consideration from Sanofi to terminate the alliance for sotagliflozin

+ References

No definition available.

+ Details

Name:	lxrx_Lxrx_Sanofiterminationagreement
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance

+ References

No definition available.

+ Details

Name:	lxrx_Lxrx_Sanofiterminationcashpayment
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

lxrx_deferred revenue balance - represents the remaining amount that had been allocated to a performance obligation, which was recorded in deferred revenue, including short and long term, that has been satisfied as part of the termination of the alliance with Sanofi

+ References

No definition available.

+ Details

Name:	lxrx_Lxrx_deferredrevenuebalance
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

lxrx_sanofi future cash payment - represents the future cash payment to be made by Sanofi as part of the termination of the alliance

+ References

No definition available.

+ Details

Name:	lxrx_Lxrx_sanofifuturecashpayment
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the development milestones relating to the achievement of positive results in certain Phase 3 clinical trials in type 2 diabetes patients.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiDevelopmentMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the milestone based on the results of an outcomes study in type 2 diabetes patients the completion of which would likely occur after initial regulatory approval.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiOutcomesStudyMilestone
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the regulatory milestones relating to the first commercial sale following regulatory approval of sotagliflozin for type 1 and type 2 diabetes in each of the United States and Europe.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRegulatoryMilestones
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRevenueAllocatedtoFundingDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRevenueAllocatedtoLicenseDeliverable
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiRevenueRecognized
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiSalesMilestonePayments
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement.

+ References

No definition available.

+ Details

Name:	lxrx_SanofiUpfrontPayment
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration